- Home
- TLSI vs HEQ Comparison
TLSI vs HEQ Comparison
Compare TLSI & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- HEQ
- Stock Information
- Founded
- TLSI 2010
- HEQ 2011
- Country
- TLSI United States
- HEQ United States
- Employees
- TLSI N/A
- HEQ N/A
- Industry
- TLSI Medical Specialities
- HEQ Investment Managers
- Sector
- TLSI Health Care
- HEQ Finance
- Exchange
- TLSI Nasdaq
- HEQ Nasdaq
- Market Cap
- TLSI 150.0M
- HEQ 130.4M
- IPO Year
- TLSI N/A
- HEQ N/A
- Fundamental
- Price
- TLSI $4.80
- HEQ $10.56
- Analyst Decision
- TLSI Strong Buy
- HEQ
- Analyst Count
- TLSI 5
- HEQ 0
- Target Price
- TLSI $10.90
- HEQ N/A
- AVG Volume (30 Days)
- TLSI 95.6K
- HEQ 43.1K
- Earning Date
- TLSI 11-13-2025
- HEQ 01-01-0001
- Dividend Yield
- TLSI N/A
- HEQ 9.78%
- EPS Growth
- TLSI N/A
- HEQ N/A
- EPS
- TLSI N/A
- HEQ N/A
- Revenue
- TLSI $35,990,000.00
- HEQ N/A
- Revenue This Year
- TLSI $56.79
- HEQ N/A
- Revenue Next Year
- TLSI $54.15
- HEQ N/A
- P/E Ratio
- TLSI N/A
- HEQ N/A
- Revenue Growth
- TLSI 45.50
- HEQ N/A
- 52 Week Low
- TLSI $3.42
- HEQ $9.08
- 52 Week High
- TLSI $5.88
- HEQ $11.84
- Technical
- Relative Strength Index (RSI)
- TLSI 51.02
- HEQ 37.91
- Support Level
- TLSI $4.41
- HEQ $10.57
- Resistance Level
- TLSI $4.93
- HEQ $10.74
- Average True Range (ATR)
- TLSI 0.28
- HEQ 0.08
- MACD
- TLSI -0.05
- HEQ -0.03
- Stochastic Oscillator
- TLSI 42.25
- HEQ 0.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.